Qi‐En Wang
YOU?
Author Swipe
View article: BNIP3L/BNIP3‐Mediated Mitophagy Contributes to the Maintenance of Ovarian Cancer Stem Cells
BNIP3L/BNIP3‐Mediated Mitophagy Contributes to the Maintenance of Ovarian Cancer Stem Cells Open
Ovarian cancer remains the most lethal gynaecological malignancy, with tumour recurrence and chemoresistance posing significant therapeutic challenges. Emerging evidence suggests that cancer stem cells (CSCs), a rare subpopulation within t…
View article: HO-3867 mediated modulation of Extracellular vesicles and Tumor microenvironment: A novel immunotherapeutic strategy for ovarian cancer
HO-3867 mediated modulation of Extracellular vesicles and Tumor microenvironment: A novel immunotherapeutic strategy for ovarian cancer Open
Introduction Ovarian cancer (OC) remains the most lethal gynecologic malignancy, with poor long-term survival, largely due to its diagnosis at advanced stages and its high rate of recurrence with resistance to platinum therapies. This stud…
View article: Circulating extracellular vesicles protein expression for early prediction of platinum-resistance in high-grade serous ovarian cancer
Circulating extracellular vesicles protein expression for early prediction of platinum-resistance in high-grade serous ovarian cancer Open
Platinum resistance in high-grade serous ovarian carcinoma (HGSOC) portends a poor prognosis. Although initial platinum-based chemotherapy response rates are high, 15-20% of patients demonstrate primary resistance to platinum therapy and a…
View article: XPC loss-of-function triggers melanomagenesis through <i>CDKN2A</i> downregulation
XPC loss-of-function triggers melanomagenesis through <i>CDKN2A</i> downregulation Open
We identified a novel XPC variant, c.2420+5G>A (XPCvar), in siblings with multiple melanomas, inherited alongside c.779+1G>T, which results in an absent or disrupted protein. However, they did not exhibit significantly higher nucleotide ex…
View article: The thioredoxin system determines CHK1 inhibitor sensitivity via redox-mediated regulation of ribonucleotide reductase activity
The thioredoxin system determines CHK1 inhibitor sensitivity via redox-mediated regulation of ribonucleotide reductase activity Open
Checkpoint kinase 1 (CHK1) is critical for cell survival under replication stress (RS). CHK1 inhibitors (CHK1i’s) in combination with chemotherapy have shown promising results in preclinical studies but minimal efficacy with substantial to…
View article: Table S2 from A Novel miR-146a-POU3F2/SMARCA5 Pathway Regulates Stemness and Therapeutic Response in Glioblastoma
Table S2 from A Novel miR-146a-POU3F2/SMARCA5 Pathway Regulates Stemness and Therapeutic Response in Glioblastoma Open
Table S2. Antibodies used in the study
View article: Figure S2 from A Novel miR-146a-POU3F2/SMARCA5 Pathway Regulates Stemness and Therapeutic Response in Glioblastoma
Figure S2 from A Novel miR-146a-POU3F2/SMARCA5 Pathway Regulates Stemness and Therapeutic Response in Glioblastoma Open
Fig. S2 Effect of miR-146a on cell invasion in U87MG/EGFRvIII, GBM30, 08-387, and LN229 cells
View article: Table S6 from A Novel miR-146a-POU3F2/SMARCA5 Pathway Regulates Stemness and Therapeutic Response in Glioblastoma
Table S6 from A Novel miR-146a-POU3F2/SMARCA5 Pathway Regulates Stemness and Therapeutic Response in Glioblastoma Open
Table S6. Multivariable analyses of clinic-pathologic parameters of overall survival in patient with GBM in CGGA database
View article: Table S4 from A Novel miR-146a-POU3F2/SMARCA5 Pathway Regulates Stemness and Therapeutic Response in Glioblastoma
Table S4 from A Novel miR-146a-POU3F2/SMARCA5 Pathway Regulates Stemness and Therapeutic Response in Glioblastoma Open
Table S4. Multivariable analyses of clinic-pathologic parameters with MGMT methylation status in patient with GBM
View article: Figure S6 from A Novel miR-146a-POU3F2/SMARCA5 Pathway Regulates Stemness and Therapeutic Response in Glioblastoma
Figure S6 from A Novel miR-146a-POU3F2/SMARCA5 Pathway Regulates Stemness and Therapeutic Response in Glioblastoma Open
Fig. S6 miR-146a enhances TMZ sensitivity in GBM30 cells
View article: Supplementary Methods, Figures 1 - 3, Tables 1 - 2 from DNA Damage-Binding Complex Recruits HDAC1 to Repress Bcl-2 Transcription in Human Ovarian Cancer Cells
Supplementary Methods, Figures 1 - 3, Tables 1 - 2 from DNA Damage-Binding Complex Recruits HDAC1 to Repress Bcl-2 Transcription in Human Ovarian Cancer Cells Open
PDF file - 440K, Supplementary Figure 1. DDB2 expression is inversely correlated with Bcl-2 expression in human ovarian cancer cells and tissues. Supplementary Figure 2. Recruitment of transcription factor E2F1 and Sp1 to the bcl-2 promote…
View article: Table S1 from A Novel miR-146a-POU3F2/SMARCA5 Pathway Regulates Stemness and Therapeutic Response in Glioblastoma
Table S1 from A Novel miR-146a-POU3F2/SMARCA5 Pathway Regulates Stemness and Therapeutic Response in Glioblastoma Open
Table S1. Primers used in the study
View article: Figure S1 from A Novel miR-146a-POU3F2/SMARCA5 Pathway Regulates Stemness and Therapeutic Response in Glioblastoma
Figure S1 from A Novel miR-146a-POU3F2/SMARCA5 Pathway Regulates Stemness and Therapeutic Response in Glioblastoma Open
Fig. S1 miR-146a inhibits cell proliferation of PDX lines GBM12 and GBM43
View article: Supplementary Tables S1-S2 and Figures S1-S11 from ALDH1A1 Contributes to PARP Inhibitor Resistance via Enhancing DNA Repair in BRCA2<sup>−/−</sup> Ovarian Cancer Cells
Supplementary Tables S1-S2 and Figures S1-S11 from ALDH1A1 Contributes to PARP Inhibitor Resistance via Enhancing DNA Repair in BRCA2<sup>−/−</sup> Ovarian Cancer Cells Open
Supplemental table S1 shows siRNA sequences. Table S2 shows primer sequences used for RTPCR. Figure S1 shows sensitivity of various cells to olaparib. Figure S2 shows the effect of olaparib on ALDHbr population. Figure S3 shows expression …
View article: Figure S10 from A Novel miR-146a-POU3F2/SMARCA5 Pathway Regulates Stemness and Therapeutic Response in Glioblastoma
Figure S10 from A Novel miR-146a-POU3F2/SMARCA5 Pathway Regulates Stemness and Therapeutic Response in Glioblastoma Open
Fig. S10 Expression of POU3F2 in TCGA datasets
View article: Figure S7 from A Novel miR-146a-POU3F2/SMARCA5 Pathway Regulates Stemness and Therapeutic Response in Glioblastoma
Figure S7 from A Novel miR-146a-POU3F2/SMARCA5 Pathway Regulates Stemness and Therapeutic Response in Glioblastoma Open
Fig. S7 Expression of miR-146a in GEO Profiles database: GSE23806
View article: Figure S6 from A Novel miR-146a-POU3F2/SMARCA5 Pathway Regulates Stemness and Therapeutic Response in Glioblastoma
Figure S6 from A Novel miR-146a-POU3F2/SMARCA5 Pathway Regulates Stemness and Therapeutic Response in Glioblastoma Open
Fig. S6 miR-146a enhances TMZ sensitivity in GBM30 cells
View article: Figure S9 from A Novel miR-146a-POU3F2/SMARCA5 Pathway Regulates Stemness and Therapeutic Response in Glioblastoma
Figure S9 from A Novel miR-146a-POU3F2/SMARCA5 Pathway Regulates Stemness and Therapeutic Response in Glioblastoma Open
Fig. S9 POU3F2 and SMARCA5 are two target candidates of miR-146a
View article: Figure S8 from A Novel miR-146a-POU3F2/SMARCA5 Pathway Regulates Stemness and Therapeutic Response in Glioblastoma
Figure S8 from A Novel miR-146a-POU3F2/SMARCA5 Pathway Regulates Stemness and Therapeutic Response in Glioblastoma Open
Fig. S8 Expression of cancer stem cell markers after overexpression of miR-146a in GBM cells
View article: Figure S15 from A Novel miR-146a-POU3F2/SMARCA5 Pathway Regulates Stemness and Therapeutic Response in Glioblastoma
Figure S15 from A Novel miR-146a-POU3F2/SMARCA5 Pathway Regulates Stemness and Therapeutic Response in Glioblastoma Open
Fig.S15 POU3F2 and SMARCA5 are positively correlated with each other in GBM cohorts
View article: Table S4 from A Novel miR-146a-POU3F2/SMARCA5 Pathway Regulates Stemness and Therapeutic Response in Glioblastoma
Table S4 from A Novel miR-146a-POU3F2/SMARCA5 Pathway Regulates Stemness and Therapeutic Response in Glioblastoma Open
Table S4. Multivariable analyses of clinic-pathologic parameters with MGMT methylation status in patient with GBM
View article: Data from ALDH1A1 Contributes to PARP Inhibitor Resistance via Enhancing DNA Repair in BRCA2<sup>−/−</sup> Ovarian Cancer Cells
Data from ALDH1A1 Contributes to PARP Inhibitor Resistance via Enhancing DNA Repair in BRCA2<sup>−/−</sup> Ovarian Cancer Cells Open
Poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi) are approved to treat recurrent ovarian cancer with BRCA1 or BRCA2 mutations, and as maintenance therapy for recurrent platinum-sensitive ovarian cancer (BRCA wild-type or mutated) aft…
View article: Data from DNA Damage-Binding Complex Recruits HDAC1 to Repress Bcl-2 Transcription in Human Ovarian Cancer Cells
Data from DNA Damage-Binding Complex Recruits HDAC1 to Repress Bcl-2 Transcription in Human Ovarian Cancer Cells Open
Elevated expression of the antiapoptotic factor Bcl-2 is believed to be one of the contributing factors to an increased relapse rate associated with multiple cisplatin-resistant cancers. DNA damage-binding protein complex subunit 2 (DDB2) …
View article: Supplementary Methods, Figures 1 - 3, Tables 1 - 2 from DNA Damage-Binding Complex Recruits HDAC1 to Repress Bcl-2 Transcription in Human Ovarian Cancer Cells
Supplementary Methods, Figures 1 - 3, Tables 1 - 2 from DNA Damage-Binding Complex Recruits HDAC1 to Repress Bcl-2 Transcription in Human Ovarian Cancer Cells Open
PDF file - 440K, Supplementary Figure 1. DDB2 expression is inversely correlated with Bcl-2 expression in human ovarian cancer cells and tissues. Supplementary Figure 2. Recruitment of transcription factor E2F1 and Sp1 to the bcl-2 promote…